Skip to content

Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone

A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02511730
Enrollment
100
Registered
2015-07-30
Start date
2015-06-30
Completion date
2015-08-31
Last updated
2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Mammography

Brief summary

The purpose of this pilot is to provide credible performance estimate information in order to conduct subsequent reader studies.

Detailed description

This pilot reader study was to determine the following: 1. the radiologist's performance metrics for the two reading modalities, i.e., FFDM read on the Aspire Bellus workstation and FFDM read in conjunction with DBT read on the Aspire Bellus workstation,; 2. the magnitude and direction of differences between performance metrics for the two modalities; and 3. variance components and correlations that would influence samples sizes and case mix for the subsequent pivotal reader study comparing performance metrics between the two modalities.

Interventions

FujiFilm Aspire Cristalle System

DEVICEFFDM

FujiFilm Aspire Cristalle System

Sponsors

Fujifilm Medical Systems USA, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Female subjects participating in FMSU004A protocol with known clinical status

Exclusion criteria

* Subjects with unknown clinical status not participating in FMSU004A protocol.

Design outcomes

Primary

MeasureTime frameDescription
Compare Per Subject Area Under Curve (AUC): FFDM Only vs DBT Plus FFDM1 monthBreast AUC performance metrics to determine if FFDM plus DBT improved cancer detection rate, requiring correct lesion localization. Statistician to estimate AUCs for each reader in each review condition (FFDM read in conjunction with FFDM plus DBT read) based on their Probability of Malignancy (POM) scores. POM scores will require correct lesion localization, such that in a case with cancer if the reader recorded one or more findings in the case but none of them are determined by the truther to match the location(s) of any proven malignancies, a POM score of 0 will be assigned to the case. Statistician to provide graphical representations of each reader's ROC curve for each review condition. For each reader the difference between the AUC for the FFDM read in conjunction with the FFDM plus DBT will be presented. Statistician to perform MRMC comparison of AUC's between FFDM read in conjunction with FFDM plus DBT using the MRMC method of Dorfman, Berbaum & Metz (1992).

Countries

United States

Participant flow

Recruitment details

The 100 breast screening and diagnostic cases selected for this study, were obtained from the FMSU2013-004A acquisition study. The statistician randomly selected cases to provide a distribution of density, finding types, etc.

Pre-assignment details

Each radiologist read all 100 cases as FFDM only and FFDM+DBT(100 cases multiplied by 2 modalities = 200 reads) with a 4 week washout period between the 2 sessions.

Participants by arm

ArmCount
All 100 Cases/Study Participants
Each case contributed 2 sets of images: FFDM only as well as DBT plus FFDM. Therefore there were 200 reads acquired from the 100 cases/participants.
100
Total100

Baseline characteristics

CharacteristicAll 100 Cases/Study Participants
Age, Customized
Participant Age
58 years
STANDARD_DEVIATION 10.3
Race/Ethnicity, Customized
Asian
3 Participants
Race/Ethnicity, Customized
Black or African American
8 Participants
Race/Ethnicity, Customized
Other/Unknown
2 Participants
Race/Ethnicity, Customized
White
87 Participants
Region of Enrollment
United States
100 Participants
Sex: Female, Male
Female
100 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1000 / 100
other
Total, other adverse events
0 / 1000 / 100
serious
Total, serious adverse events
0 / 1000 / 100

Outcome results

Primary

Compare Per Subject Area Under Curve (AUC): FFDM Only vs DBT Plus FFDM

Breast AUC performance metrics to determine if FFDM plus DBT improved cancer detection rate, requiring correct lesion localization. Statistician to estimate AUCs for each reader in each review condition (FFDM read in conjunction with FFDM plus DBT read) based on their Probability of Malignancy (POM) scores. POM scores will require correct lesion localization, such that in a case with cancer if the reader recorded one or more findings in the case but none of them are determined by the truther to match the location(s) of any proven malignancies, a POM score of 0 will be assigned to the case. Statistician to provide graphical representations of each reader's ROC curve for each review condition. For each reader the difference between the AUC for the FFDM read in conjunction with the FFDM plus DBT will be presented. Statistician to perform MRMC comparison of AUC's between FFDM read in conjunction with FFDM plus DBT using the MRMC method of Dorfman, Berbaum & Metz (1992).

Time frame: 1 month

Population: The study employed a fully factorial, counterbalanced crossover design in which all readers reviewed images from all cases in two visits separated by a memory washout period of approximately 4 weeks. Each reader read half FFDM cases and half FFDM + DBT cases during each of 2 visits.

ArmMeasureValue (MEAN)Dispersion
FFDM Plus DBTCompare Per Subject Area Under Curve (AUC): FFDM Only vs DBT Plus FFDM100 ProbabilityStandard Error 0.812
FFDMCompare Per Subject Area Under Curve (AUC): FFDM Only vs DBT Plus FFDM100 ProbabilityStandard Error 0.78

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026